← Sage — Cardiology · Sage hub

Sage — A Metabolic Hypothesis of Hypertension

Pressure as Readout, Resistance as Scar

This essay presents a metabolic and evolutionary hypothesis for educational and philosophical purposes. It is not medical advice, diagnosis, or treatment. Blood-pressure medicines are physician-guided. Do not start, stop, or change any medicine because of what you read here; talk with your own physician about your own pressure and your own treatment.

Introduction: The Number and the Engine

Primary, or essential, hypertension is conventionally described as a multifactorial disorder of vascular tone, renal sodium handling, sympathetic overactivity, and renin–angiotensin activation. Treatment is lifelong antihypertensive pharmacotherapy aimed at those effectors. That description is useful, and the drugs that follow from it are valuable. It is also incomplete.

Modern medicine measures the dashboard. Blood pressure, LDL, glucose, weight, and even inflammation are downstream compensations. The engine is ATP-generating capacity. When that engine has headroom, tissues repair, hormones partition fuel honestly, immune cells can resolve rather than smolder, and muscle can both grow and stay oxidative. When it does not, the organism enters chronic compensatory mode. Fat is defended. Glucose is elevated. Pressure rises. Mitochondria fragment. The named diseases arrive later, as archives of that failure.

This essay advances the hypothesis that mitochondrial bioenergetic dysfunction and redox imbalance are the upstream metabolic driver of much primary hypertension. Cuff pressure is a form. So are vessel diameter and eNOS as a protein that is present or absent. The function is whether mitochondria are paid in ATP relative to load, and whether coupled nitric oxide is matching delivery, consumption, and conduit protection to that load. Function determines form. When matching works, the wall stays competent. When it fails, form degrades into the shapes we then name as separate diseases.

The named diseases are not independent entities but visible clusters of one process: the body's response when ATP load outruns ATP-generating capacity. This is unification under the most conserved imperative in biology, the metabolic persistence of the organism. Hypertension belongs in that family, with the extra complexity that its scar is cross-system: endothelium, resistance artery, conduit wall, sympathetic tone, and kidney. That complexity does not diminish the root.

The Engine Beneath the Pressure

The toll-keeper

The bioenergetic bridge into this model, the chemiosmotic view of life in the tradition of Nick Lane, is simple. Food electrons descend the mitochondrial electron transport chain in stepwise redox reactions. Energy extracted along that descent powers proton pumps. The resulting chemiosmotic force drives protons back through ATP synthase, which collects a toll of roughly three ATP for each full turn of its proton-driven rotor. Everything that looks like physiology, vascular tone included, is downstream of whether that toll-keeper is supplied with oxygen, reducing equivalents, and an intact membrane, and whether the ATP so collected is sufficient for the load the tissue is asked to carry.

Vessels exist to deliver the two substrates the toll-keeper cannot do without: oxygen as the terminal electron acceptor, and metabolic fuel as the source of high-energy electrons. The respiratory system sets arterial oxygen content. The heart and vessels distribute it. Local metabolites, sympathetic tone, and endothelial signals dilate the beds that are working. This is not a separate energy system. It is the plumbing without which the engine cannot run. Treating the vessel only as a pressure gadget is the category error at the center of form-first medicine.

The compensatory cascade

The organizing rule is the compensatory cascade. When ATP load exceeds ATP-generating capacity, the body reverts to lower, older, less flexible ways of making and spending energy. Acute emergency mode is adaptive: it saves the hour. Restoring capacity in time lets the system stand down. When the mismatch persists, the same programs become a chronic, Warburg-like operating mode, and selection and remodeling can lock them in. That locked state is what we meet in clinic as disease.

In this model, the Crabtree and Warburg effects mark the two ends of this spectrum. The Crabtree effect is acute and reversible: oxidative phosphorylation is suppressed while metabolic flexibility is kept. The Warburg effect is persistent: a dependency on substrate-level phosphorylation with lost flexibility. Early in many compensatory states, including the initial response of endothelial or smooth-muscle cells to increased demand, the dashboard reading changes but the engine retains the capacity to return to baseline. Later, the same program runs long enough to be reified as a named disease. The named syndromes, hypertension among them, are visible clusters of these locked compensatory responses.

Aerobic glycolysis is not a cancer-only curiosity. It is a conserved compensatory program in any cell whose oxidative capacity is insufficient relative to its need to persist, proliferate, or fight. Activated macrophages, effector T cells, angiogenic endothelial cells, and proliferating vascular smooth muscle run the same shift. Healthy endothelium already runs a surprisingly glycolytic program. In atherogenic flow, hypoxia, and a cytokine bath that program intensifies, mitochondria falter, and the wall begins to behave like a wound that will not close.

Nitric Oxide: The Flux Manager

Nitric oxide is conventionally taught as a vasodilator. That description is true and incomplete. The textbook cascade is correct as far as it goes. Endothelial nitric oxide synthase oxidizes L-arginine to NO. NO diffuses into adjacent vascular smooth muscle, activates soluble guanylate cyclase, raises cGMP, activates protein kinase G, lowers cytosolic calcium, and relaxes the cell. In the systemic vasculature, endothelial cells sense shear stress and stretch and activate eNOS; the resulting relaxation lowers peripheral resistance and blood pressure.

On this hypothesis, NO is better understood as an energy-flux manager: a short-lived gas whose physiologic job is to keep mitochondrial ATP generation aligned with tissue load. It does this in three coordinated acts.

Act I: delivery. Working tissue opens downstream arterioles. Flow through the parent artery rises. Laminar wall shear is transduced by endothelial mechanosensors (PIEZO1, the glycocalyx, integrins, purinergic receptors after ATP release) into calcium entry and eNOS phosphorylation. More NO is made. Feed arteries dilate. Perfusion pressure is preserved while the microcirculation is open, and the tree scales together instead of the smallest vessels dumping pressure. Over hours to days the same shear writes more eNOS. Regular high energy flux, which is to say training, is the chronic instruction that keeps the delivery system competent.

Local metabolic and redox signals start the opening. One proposed error-signal model holds that when oxygen and substrate delivery are adequate, interstitial superoxide quenches NO before it reaches arteriolar smooth muscle. When mitochondria begin to consume oxygen and reducing equivalents, superoxide emission falls, more NO survives, and the arteriole opens. In that model, demand is reported as the withdrawal of an inhibitor of NO, not only as the secretion of a new dilator.

Act II: rationing. The same NO that opened the vessel binds cytochrome c oxidase, the last enzyme before oxygen becomes water. At the nanomolar concentrations produced by eNOS, inhibition is partial and reversible. Cells nearest the capillary consume oxygen a little more slowly, so oxygen is spared to diffuse farther into the tissue. This is not poisoning the engine. It may prevent the first mitochondria along the oxygen gradient from monopolizing the terminal acceptor.

Act III: conduit protection. The same low-flux, eNOS-derived NO restrains leukocyte adhesion, platelet aggregation, endothelial permeability and lipoprotein influx, and vascular smooth-muscle proliferation and migration. A lumen that stays clean is a lumen that can still deliver.

When these three acts run, energy flux can be high: more substrate in, more oxygen appropriately distributed, more ATP out, less need for glycolytic rescue. When they fail, the cell faces the same upstream deficit: insufficient oxidative ATP relative to the cost of remaining ordered.

Smooth muscle is the valve; skeletal muscle is the load

Vascular smooth muscle is the effector of the NO–cGMP valve. Tone in arterioles and feed arteries is set by cytosolic calcium and the phosphorylation state of the contractile apparatus; cGMP and PKG lower that calcium and relax the cell. Skeletal muscle fibers are the load. Their contraction does not run on cGMP. Fiber-derived NO modestly aids local hyperemia and glucose uptake, but exercise hyperemia is redundant by design: metabolites, the muscle pump, prostaglandins, endothelium-derived hyperpolarization, and neural inputs all participate. When we speak of NO regulating vascular flow, we mean smooth muscle in the wall of the vessel that feeds the mitochondrion.

Acute Matching: Ohm's Law During the Good Compensation

Mean arterial pressure is cardiac output times total peripheral resistance. In the electrical analogy, V = I × R. During exercise the terms move in opposite directions, and that is the point.

Working muscle accumulates metabolites and NO. Arteriolar resistance in that bed falls. Total peripheral resistance falls with it, though inactive beds constrict under sympathetic drive, so the whole-body drop is smaller than the local one. Cardiac output rises several-fold. Because the rise in flow exceeds the fall in resistance, systolic pressure and usually mean pressure rise even while the working muscle is dilated. Flow to that muscle can increase an order of magnitude. The pressure rise is the residual of driving a large current through a still-finite arterial tree. It is not the purpose of the act. The purpose is delivery.

That is hormesis and good compensation. The mismatch, load above current output, is brief. NO and metabolites open conductance. The heart fills the open bed. After the bout, conductance stays high for a while and pressure often falls. Repeated bouts write more eNOS and more mitochondrial volume. The next mismatch is smaller relative to capacity.

Two errors follow if this physiology is misread. The first is to treat the exercise pressure rise as "hypertension doing its job," as if high cuff pressure were the matching variable. Flow is the matching variable. Pressure is what is left when current and resistance have moved. The second is to treat chronic hypertension as the same act left running. It is not. In healthy exercise, resistance in the working bed falls and flow soars. In established essential hypertension, resistance is high and cardiac output is normal or low. The patient is paying a pressure tax without buying proportional tissue perfusion. That is failed matching, not completed compensation.

Hypertension as Scar, Not as Successful Compensation

The scar grammar

A scar, in this model, is locked-in tissue and set-point change after a compensatory loop has been running outside the window natural selection built it for. The scar is form. The unmatched load that would not clear is function.

Acute loop: mismatch detected → short-acting signals (NO, insulin, sympathetic drive, glycolysis) → restore ATP supply or dump load → signal turns off.

Chronic loop: mismatch never clears → the same signals stay high, or the wall and parenchyma remodel around them → the remodeling is the new physiology → the high signal is now required just to stand still, and the remodeling itself creates new mismatch.

The claim must be kept honest. Not every chronic disease begins as a single-cell ATP shortfall. Some start as substrate overflow, some as mechanical strain, some as infection or toxin. The model stays strong if the claim is this: whatever the first mismatch, biology answers with a short-loop program. If the mismatch persists, that program becomes architecture. The architecture is the scar. The scar then causes new ATP and delivery failure in neighboring systems.

Attempted compensation, failed matching

When fuel, time, and load no longer match the ancestral prior, generating capacity falls relative to demand, and the organism enters a defended mode: glycolysis runs even when oxygen is present, lipid is stored as buffer, and vessels remodel to keep pressure on underpowered beds. Hypertension emerges partly as perfusion compensation through energy-starved vessels. When peripheral ATP demand cannot be met at normal perfusion pressures because of mitochondrial limitation, the system raises pressure to maintain flow, an ancient compensatory reflex now sustained chronically. Endothelial paracrine signaling (NO via eNOS, which is energy and redox sensitive, balanced against the vasoconstrictor endothelin) is impaired by endothelial mitochondrial dysfunction, and vascular stiffness and hypertension follow as attempts to maintain perfusion pressure when microcirculatory efficiency falls.

The sharper reading keeps the compensatory root but refuses a tempting shortcut. It is tempting to say that hypertension is the vessel's successful attempt to compensate for insufficient ATP generation relative to load. The exercise data make that shortcut look better than it is. In exercise, pressure rises because flow rises more than resistance falls. In chronic hypertension, resistance is the standing problem.

1. The valve stays stiff. Endothelial ATP and redox failure uncouple eNOS. Superoxide eats NO. The valve that should drop resistance when load rises stays stiff.

2. The wall remodels. Chronically high pressure plus oscillatory shear remodel the wall: more collagen, less elastin, vascular smooth-muscle hypertrophy. That locks in higher peripheral resistance and pulse pressure. Arteriosclerosis (medial stiffening) and atherosclerosis (intimal plaque) are related locks, not identical ones. Stiff conduit arteries raise systolic pressure even when mean resistance is only modestly up.

3. The kidney resets. The kidney resets pressure-natriuresis around the new pressure. Sympathetic and renin–angiotensin tone keep the set point high. That is how a delivery-system failure becomes a standing high-pressure state.

What is not accurate is to say the organism is choosing higher blood pressure so mitochondria get more ATP. The scar is high resistance and a reset kidney. Pressure is the readout: form, not the matching variable. We are not looking at completed compensation. We are looking at the residue of a matching loop that can no longer close, then the remodeling that makes the loop even harder to close. Hypertension is usually a delivery-system scar that secondarily worsens the ratio of ATP output to demand.

The two readings meet in the cascade itself. The acute move, raising pressure to keep flow through underpowered tissue, is an attempt at compensation. Left on, it does not pay the tissue back. It becomes architecture.

A simultaneous failure

Hypertension is not one location of ATP deficit. Kidney, sympathetic nerves, endothelium, and vascular smooth muscle all run matching programs, and chronic endothelial energy and redox failure can start several of them at once. Hypertension is the simultaneous failure of the normal homeostatic operating procedure in every bed that shares the same endothelium and the same renal set-point machinery.

The Endothelium Under Energy Failure

Endothelial dysfunction, meaning reduced NO bioavailability, is a hallmark of hypertension, driving vasoconstriction, vascular remodeling, and stiffness. The metabolic question is why the NO fails.

Uncoupling

Mitochondrial reactive oxygen species oxidize tetrahydrobiopterin (BH4), uncoupling eNOS so that it produces superoxide instead of NO. On this hypothesis, that is a central mechanism of endothelial dysfunction in hypertension. Oxidative stress reacts NO with superoxide to form peroxynitrite, depletes BH4, raises ADMA, and uncouples the synthase so that the enzyme itself produces superoxide. The delivery manager becomes a source of the damage it was meant to prevent. NO synthesis is energetically expensive and redox-sensitive; endothelial NO deficiency is itself downstream of mitochondrial insufficiency in the endothelium.

Systemic hypertension features downregulated SIRT3, inactivated SOD2, and mitochondrial oxidative stress that promotes vascular fibrosis and stiffness. In hypertension models, preserving these mitochondrial antioxidant defenses, or recoupling eNOS, attenuates remodeling.

There is a dual face, and it must be stated without sentimentality. High-output inducible NO, or uncoupled eNOS plus abundant superoxide, generates concentrations of NO and peroxynitrite that nitrate proteins, further uncouple the synthase, and injure mitochondria. Flooding the system with NO donors is therefore not a clean strategy. The signal is not the enemy; the inefficient, uncoupled source is.

Mechanosensing collapse

Mitochondria support the calcium handling and ATP-dependent processes required for TRPV4, PIEZO, and integrin signaling. Their failure blunts the adaptive responses of vascular endothelium to shear and stretch. In mice and endothelial cells, PIEZO1 converts shear into calcium and a cascade that includes ATP release, P2Y2 signaling, and Akt phosphorylation of eNOS, and, over time, shear raises transcription of the enzyme. Disturbed oscillatory shear at bifurcations activates a different program, NF-κB, adhesion molecules, and superoxide, and that is where plaques begin. The geometry of flow writes the biology of the wall.

What shifts the endothelium

Several inputs push the endothelium toward this failure. In this model, chronic hyperinsulinemic and seed-oil-dominant patterns that impair mitochondrial handling also impair the redox environment eNOS requires. Linoleic-acid peroxidation products form adducts with electron-transport proteins, amplify ROS, and contribute to endothelial and vascular injury. Lp(a) particles carry oxidized phospholipids; independent of ApoB levels, higher Lp(a) correlates with elevated vascular superoxide and eNOS uncoupling secondary to BH4 depletion, and its oxidized cargo drives an endothelial glycolytic shift that recapitulates a pseudo-hypoxic, Warburg-like state. Smoking promotes insulin resistance and endothelial injury. The gut matters too: short-chain fatty acids support eNOS, while dysbiosis, trimethylamine N-oxide, and lipopolysaccharide crossing a compromised barrier promote endothelial dysfunction and systemic inflammation.

The Wall: Macrophages, Matrix, and Mineral

Innate immune participation

In hypertension and its vascular complications, especially atherosclerosis, macrophages infiltrate the vessel wall, become foam cells, amplify oxidative stress and inflammation, and drive matrix deposition and plaque formation. Perivascular macrophages and vascular smooth-muscle phenotypic switching further entrench remodeling. The upstream signals include oxidative stress and energy deficit. Mitochondrial ROS and impaired NAD+ metabolism favor pro-inflammatory polarization and inflammasome activation while impairing resolution. Chronic low-grade inflammation sustains the vicious cycles of endothelial dysfunction and matrix pathology. Trained immunity can lock a glycolytic, hyper-responsive set point into long-lived myeloid cells and even into endothelial and smooth-muscle cells.

Matrix and stiffness

In hypertension, large and resistance arteries undergo matrix remodeling: elastic fiber fragmentation, excessive collagen deposition (types I and III), proteoglycan changes, and loss of compliance. The result is arterial stiffness that elevates systolic pressure and perpetuates end-organ damage. TGF-β, CTGF, integrins, Rho-kinase (ROCK), and mechanosensing through focal adhesions mediate the switch of vascular smooth muscle toward myofibroblast-like states and matrix accumulation.

The feedback is mechanical. Increased stiffness or altered strain amplifies profibrotic signaling: integrin clustering → RhoA → ROCK → myosin light chain phosphorylation → more matrix. The matrix is not passive scaffolding. It feeds back on cellular phenotype. Smooth muscle that leaves its contractile, oxidative state becomes synthetic, migratory, and glycolytic, another Warburg-like shift that supports proliferation and matrix deposition. Rho-kinase inhibitors such as fasudil have been studied in hypertension and vascular remodeling; they address this downstream contractility and matrix axis but do not restore mitochondrial health.

Plaque and calcium

Once calcified and stiff, plaque writes the next pressure and flow field. Endothelial dysfunction with reduced NO bioavailability is among the earliest events in atherogenesis, and hypertension sits among the risk factors whose final common path is the oxidative uncoupling of eNOS. Arterial calcification belongs to the same story. Medial or intimal vascular calcification is driven upstream by mitochondrial calcium mishandling secondary to energy failure, and vascular calcification and osteoporosis frequently coexist as one redistribution problem. Persistent fibrin scaffolds provide a nucleation platform for mineral. Nattokinase degrades fibrin and enhances endogenous fibrinolysis, and clinical observations of reduced carotid plaque size at higher doses are read as a matrix-remodeling action rather than pure lipid lowering. Nattokinase may add to the effect of blood thinners; combining it with anticoagulant or antiplatelet drugs is a question for your own physician.

The Cross-System Scar: Kidney, Nerves, Hormones, and Insulin

Kidney and sodium

The kidney is ATP-hungry for sodium transport; it fails when its mitochondria and their oxygen pipeline fail. Proximal tubular cells and podocytes are mitochondria-rich for active transport and filtration-barrier maintenance. In hypertension the kidney resets pressure-natriuresis around the new pressure, and renin–angiotensin tone helps hold the set point high. Peripheral dopamine is part of the same energy board: proximal tubule cells take up circulating L-DOPA and decarboxylate it to dopamine that is natriuretic and helps restrain NADPH oxidase. Low insulin is itself natriuretic. During a fast, sodium, potassium, magnesium, and phosphate leave with glycogen water and with the natriuresis of low insulin. Cardiorenal syndromes are two high-demand engine beds sharing a failing pump and a failing clean-up system.

Salt intake and salt sensitivity

Salt is not merely a volume expander. Excess sodium, particularly in the insulin-resistant or energy-constrained host, damages mitochondrial structure (shorter mitochondria, reduced cristae, increased fission and vacuolization) and function (impaired oxidative phosphorylation, ATP production, calcium homeostasis, and membrane potential). It elevates mitochondrial ROS, which in turn uncouples eNOS, stiffens the valve, and impairs renal sodium excretion. Salt sensitivity of blood pressure is strongly associated with insulin resistance; roughly half of salt-sensitive individuals are insulin resistant. In this framing, the salt-sensitive phenotype is an expression of the same upstream mitochondrial and redox failure that locks the compensatory cascade. Patterns that restore metabolic flexibility reduce the need for the high-signal sodium-retention programs; chronic hyperinsulinemic, seed-oil-dominant patterns amplify them.

Sympathetic drive, renin–angiotensin, and the locked set-point

Sympathetic overdrive raises vascular tone and is one of the routes by which cardiometabolic syndrome amplifies risk. Chronic cortisol activation mobilizes substrate when cellular ATP production falters; short-term it is adaptive, long-term it is catabolic and contributes to sarcopenia, central obesity, hypertension, and further mitochondrial stress. The renin–angiotensin system runs in parallel. Angiotensin II is not only a vasoconstrictor; it generates ROS, promotes inflammation, and contributes to the uncoupling and remodeling that keep resistance high. Both loops are short-acting signals that become architecture when the mismatch never clears. The kidney resets pressure-natriuresis around the new pressure; sympathetic and renin–angiotensin tone hold the set point. What begins as an attempt to maintain perfusion through underpowered beds becomes the standing high-pressure state.

Kidney disease as downstream scar

Sustained high resistance and a reset pressure set-point produce the secondary scar of hypertensive nephropathy. Tubular cells and the interstitium, already energy-constrained, experience chronic pressure and oxidative load. The result is nephrosclerosis, interstitial fibrosis, and progressive loss of excretory reserve—another locked compensatory response that then feeds back on volume and pressure control. The same mitochondrial attrition that impairs sodium handling also impairs the kidney's ability to stand down once the systemic matching loop has failed.

Insulin resistance: a scar of tolerance

Acute hyperinsulinemia is compensation. Chronic hyperinsulinemia is the loop left on. Receptors down-regulate. Adipose expands. The liver keeps making glucose. The same endothelium that needs coupled eNOS now lives in a high-insulin, high-ROS, high-free-fatty-acid milieu linked to endothelial dysfunction and eNOS uncoupling. The tolerance is the scar: the dose that saved the hour becomes the milieu that ruins the decade. The scar then writes the next ones: endothelial energy and redox failure, plaque, and stiff pressure. This is why the metabolic syndrome cluster (insulin resistance, obesity, dyslipidemia) travels with hypertension. On this hypothesis they share the same upstream bioenergetic driver. Impaired oxidative phosphorylation drives glycolytic compensation; hyperinsulinemia forces glucose uptake while driving hepatic VLDL oversecretion and blocking adipose lipolysis; and hypertension emerges partly as perfusion compensation through energy-starved vessels.

Breathing at night

Obstructive sleep apnea imposes chronic intermittent hypoxia on an energy-constrained system. Cycles of hypoxia and reoxygenation impair electron-transport complexes, increase electron leak, and elevate ROS, much like repeated ischemia–reperfusion. The result is endothelial dysfunction, insulin resistance, sympathetic activation, and multi-organ comorbidity. Sleep fragmentation further disrupts the nocturnal window of mitophagy and redox restoration.

The Heart Under Pressure, the Lungs, and the Right Heart

The left ventricle

The heart is an obligatory oxidative organ, and cardiomyocytes have the highest mitochondrial volume density of any cell type. Chronic insufficiency, including from hypertension-induced pressure overload, triggers compensatory hypertrophy to normalize wall stress despite inefficient force generation. Matrix remodeling and fibrosis are repair attempts that eventually stiffen the ventricle or dilate it. Fibrosis is cheaper structurally than rebuilding cristae. Hypertrophic remodeling is an attempt to increase force under pressure load, yet the same mitochondrial attrition that made the hypertrophy necessary limits its use and promotes fibrosis. Heart failure with preserved ejection fraction is dominated by afterload-driven energy demand that outstrips mitochondrial supply, often in the setting of systemic metabolic syndrome. Systemic metabolic syndrome, circadian disruption, and absent contractile hormesis lower the threshold at which pressure overload locks these compensations into place.

Preeclampsia as an acute matching failure

Preeclampsia can be read as a pregnancy-specific, accelerated version of the same scar. Placental mitochondrial oxidative stress, reduced eNOS bioavailability, and the release of anti-angiogenic factors (notably sFlt-1) drive endothelial dysfunction, hypertension, and multi-organ involvement in the mother. Mitochondrial ROS and uncoupling in the placenta and maternal endothelium are central. Delivery remains the definitive intervention; antihypertensive agents and other measures are used under obstetric guidance. The hypothesis places the syndrome on the same energy-flux and nitric-oxide map used for essential hypertension.

Pulmonary arterial hypertension and the right heart

The right ventricle and pulmonary vasculature form the immediate interface with oxygen delivery. Pulmonary arterial hypertension shows a Warburg-like glycolytic shift in pulmonary arterial smooth-muscle cells and in right-ventricular myocytes, driven by mitochondrial hyperpolarization, excess ROS, and impaired pyruvate dehydrogenase activity. In pulmonary hypertension models, eNOS uncoupling initiates endoplasmic-reticulum stress that further impairs mitochondria; scavenging mitochondrial ROS or recoupling eNOS attenuates vascular remodeling and pressure elevation. The same high-activity lung cytochrome oxidase isoform that enables hypoxic vasoconstriction can, under chronic toxic or hypoxic load, contribute to inflammatory and apoptotic cascades that raise right-ventricular afterload. Serotonin, made by pulmonary neuroendocrine cells and taken up through the serotonin transporter in pulmonary endothelium and smooth muscle, modulates vascular tone and remodeling; elevated pulmonary SERT tracks with pulmonary hypertension in COPD. The intermittent hypoxia of sleep apnea imposes repeated ischemia–reperfusion injury on both pulmonary endothelium and right-ventricular mitochondria, promoting endothelial dysfunction and progressive right-heart strain.

Cor pulmonale is therefore not an independent entity. It is the cardiac expression of the same oxygen-delivery failure described in the pulmonary hypothesis, amplified by the continuous mechanical work of the right ventricle. On this hypothesis, restoring systemic oxidative capacity improves right-heart resilience and reduces the pulmonary vascular load that feeds it. Conventional treatments (PDE5 inhibitors, endothelin-receptor antagonists, prostacyclin-pathway agents) target the symptomatic remodeling and tone; they do not restore mitochondrial capacity. PDE5 inhibitors have their clearest clinical effect in the corpus cavernosum and in pulmonary arterioles, where PDE5 is abundant because the signal must be terminable.

The Eye as a Window: Hypertension and Glaucoma

Hypertension and primary open-angle glaucoma show striking parallels at the level of cells and tissues: endothelial-like cells regulating tone and permeability, central reliance on NO signaling, macrophage-like immune participation, and pathology centered on matrix turnover and stiffening. They share risk factors (age, metabolic syndrome features including insulin resistance and obesity, and diabetes) and respond to overlapping drug classes, including beta-blockers, rho-kinase inhibitors (approved for glaucoma, still investigational for hypertension), and agents that modulate NO or prostaglandins. Systemic hypertension is associated with open-angle glaucoma, with both high and low blood pressure linked to increased risk through effects on intraocular pressure or ocular blood flow.

The eye's conventional outflow pathway runs a remarkably analogous NO loop. Trabecular meshwork cells have smooth-muscle-like contractile properties and express eNOS, and Schlemm's canal is lined by specialized endothelium. When intraocular pressure rises, the canal narrows, shear on its endothelium rises, eNOS-derived NO relaxes the meshwork and raises inner-wall permeability, outflow increases, and pressure falls: a negative-feedback loop that directly parallels vascular autoregulation. Dysregulation of this eNOS axis produces ocular hypertension and contributes to glaucoma, just as eNOS uncoupling produces systemic hypertension. Polymorphisms in NOS3, the gene for eNOS, modify glaucoma risk and are also associated with hypertension.

Perfusion pressure at the optic nerve head is roughly mean arterial pressure minus intraocular pressure. Failed autoregulation may help explain why some people get glaucoma at "normal" pressure, and why a stiff, high-systolic, low-diastolic circulation may not be safe for the disc. Nocturnal pressure dips and nocturnal intraocular pressure peaks meet the disc at night.

Hypertension and glaucoma share a structure that a single-location story misses. Each is not one ATP deficit in one cell type but multiple simultaneous deficits from the normal operating procedure: endothelium, kidney, and resistance artery in one case; barostat, autoregulation, and high-cost axon in the other, failing together because they share chemistry and the chronic operating mode. Systemic hypertension and ocular hypertension then look less like coincidences and more like cousins: both are, in part, remodeling to keep flow through underpowered tissue, both lean on nitric oxide, both stiffen extracellular matrix, and both keep company with insulin resistance. Cardiovascular risk scores predict future glaucoma incidence, which underscores the shared systemic metabolic substrate. When mitochondria falter, multiple systems pay the price.

The same pump-and-barrier pattern in the cornea: Sage — Fuchs’ Dystrophy (shared pathways with glaucoma and hypertension).

Hypertensive retinopathy

Hypertensive retinopathy is the visible retinal counterpart of the same endothelial energy and redox failure and matrix remodeling described systemically. Chronic high pressure plus oscillatory shear produces arteriolar narrowing, arteriovenous nicking, flame hemorrhages, cotton-wool spots, and, in severe cases, disc edema. Swelling of the optic disc with very high blood pressure is a medical emergency that needs same-day care. These are form changes—scars of a matching loop that no longer closes. The retina offers a non-invasive window on the same process that stiffens conduit arteries and impairs optic-nerve-head perfusion. As with glaucoma, cardiovascular risk scores and metabolic-syndrome features predict retinal vascular changes, underscoring the shared systemic substrate.

Retinal artery and vein occlusions and NAION: Sage — Arterial and Venous Occlusions.

Lowering eye pressure is still the only treatment proven to slow glaucoma, and changes to blood-pressure or glaucoma medicines, including bedtime dosing, belong with your physician.

Reading the Dashboard and Testing the Hypothesis

What to watch

In the metabolic dashboard, blood pressure sits beside nocturnal dipping as the read-out of hypertension and vascular load. It sits with HOMA-IR, HbA1c, hsCRP, TG/HDL, visceral fat and waist-to-height, lean mass, grip, a VO2 proxy, cortisol shape, and overnight heart rate. Grip strength and VO2 max remain practical surrogates of the whole stack. Map is not terrain. Curves on the dashboard are read-outs of flux, not freestanding disease villains.

What would test it

On this hypothesis, hypertensive patients should show biomarkers of mitochondrial dysfunction: reduced NAD+/NADH ratios, elevated circulating or local 8-OHdG or mtDNA damage, and impaired endothelial bioenergetics. Mitochondria-targeted interventions should improve vascular compliance beyond what blood-pressure lowering alone achieves. Metabolic syndrome severity should correlate with mitochondrial metrics in vascular tissue.

The hypothesis is falsifiable in a further way. If chronic hypertension were successful ATP compensation, raising pressure would raise tissue ATP. It does not, in any simple way, in essential hypertension. If NO were only a vasodilator, restoring coupled eNOS or amplifying cGMP would change blood pressure without changing mitochondrial matching or plaque initiation.

Therapeutic Implications

Conventional treatment keeps its place

Current management is largely symptomatic and compartmentalized: antihypertensives for blood pressure. These interventions are valuable, yet they address downstream manifestations. NO-donating agents augment the deficient signal without correcting the oxidative uncoupling that caused it. Rho-kinase inhibitors relax contractile tone without restoring mitochondrial health. This hypothesis does not deny the use of acute pressure control in malignant hypertension or advanced disease. It reframes the chronic, mild-to-moderate essential hypertension of metabolic syndrome as a downstream signal rather than a root defect. Lowering pressure lowers load, and load reduction is a real benefit. It does not prove engine repair. A lighter car with a worn engine still wins some races; it does not become a new engine.

Blood-pressure medicines, their doses, and their timing are decisions to make with your own physician. Nothing here is a reason to stop or change one.

Drug classes, secondary causes, and measurement

The major drug classes (ACE inhibitors and ARBs, calcium-channel blockers, thiazide-type diuretics, and beta-blockers) lower the pressure readout by different routes: reducing angiotensin-II-driven ROS and remodeling, relaxing smooth-muscle tone, reducing volume, or lowering sympathetic drive. Each can be useful; none restores mitochondrial capacity or recouples eNOS. Secondary causes (renovascular disease, primary aldosteronism, pheochromocytoma, coarctation, Cushing syndrome, drug-induced hypertension, and others) are uncommon but must be considered when the history, exam, or response to treatment suggests them; evaluation belongs with a physician. Measurement thresholds and technique matter. Office readings are imperfect; ambulatory and properly performed home monitoring are preferred for diagnosis and management. Current guideline thresholds (for example, 130/80 mmHg in many frameworks) are decision aids, not biological set-points. The hypothesis treats the number as a readout of matching failure, not the disease itself.

Outcome evidence in people

Intensive blood-pressure lowering trials (for example, SPRINT) show that lower targets reduce cardiovascular events in selected high-risk populations. That finding is compatible with the load-reduction benefit of lowering the readout. At the same time, lifestyle interventions that restore fuel flexibility, circadian alignment, and contractile hormesis—ketogenic or ancestral patterns, time-restricted eating under medical supervision, progressive resistance and aerobic work, and sleep restoration—frequently produce meaningful blood-pressure reductions and, in some individuals, allow de-escalation of pharmacotherapy. These observations are consistent with the claim that addressing the upstream bioenergetic mismatch can reduce the need for the chronic high-pressure scar, but they do not replace physician-guided care or large-scale outcome trials of the full approach.

Restore the conditions the engine evolved for

If NO is an energy-flux manager, and if hypertension is a scar of matching left on, then the hypothesis prioritizes the conditions that keep the manager coupled, keep the loops pulsed rather than standing, and keep the engine supplied. Restoring mitochondrial capacity and fuel oxidation often permits blood-pressure reduction or normalization with less or no pharmacotherapy, consistent with the effects of ketogenic diets, exercise, and circadian realignment observed in hypertensive patients. Integrated care that addresses insulin sensitivity, oxidative stress, and mitochondrial support alongside conventional metrics may slow progression more effectively than isolated blood-pressure targets and reduce polypharmacy burden. Any change to diet, fasting, or training when you take blood-pressure medicines is one to make with your own physician.

Fuel

Fuel is composition for the nested symbionts, mitochondria and gut biota. Substrates mitochondria can oxidize cleanly reduce electron leak and the superoxide that uncouples eNOS. The patterns this hypothesis names are ancestral: animal fats and proteins, microbially accessible fermented carbohydrates, and intermittent ketosis, which restore metabolic flexibility, improve the NAD+/NADH ratio, and reduce inflammatory tone. Chronic hyperinsulinemic and seed-oil-dominant patterns are how the insulin loop is left on. Systemic ketosis can improve triglycerides, blood pressure, and sometimes insulin; it is partial, upstream help, and it does not automatically reverse a plaque. The advantage of a fast is the depth of the signal, and the disadvantage is the same depth: sodium, potassium, magnesium, and phosphate leave with glycogen water, and a long fast in someone whose medicines assume a fed insulin level is a larger perturbation with a narrower safety margin.

Circadian alignment

Circadian is the timing layer: it matches modern energy-flux timing to the ancestral training set through light timing, fuel timing, hormesis timing, and temperature. eNOS transcription, BH4 synthesis, and mitochondrial quality control are cyclic. Morning light, consistent sleep, and a dim evening are timing cues for the same process that converts food electrons into ATP. In the second half of the night the body begins lifting cortisol, and vascular tone is primed in the dark before waking. UVA light can release nitric oxide from skin stores and lower blood pressure, a vascular signal separate from the clock. Nocturnal pressure dipping matters, and the timing of antihypertensives is not a footnote; that timing belongs with your own physician.

Strength and conditioning

Dynamic resistance and aerobic work are the shear and load stimuli that phosphorylate eNOS today and write more of it tomorrow. They raise tissue mitochondrial volume. High energy flux done as repeated, directed work produces pulsatile laminar shear that protects eNOS; sedentary low flux plus high pressure does the reverse. Strength hormesis expands mitochondrial density and quality and, applied through progressive resistance, improves ventricular resilience and endothelial function. This is the difference between acute matching and chronic operating procedure, trained on purpose. Exercise, which looks like a lifestyle recommendation, is on this hypothesis an endothelial gene-expression therapy and a mitochondrial biogenesis therapy at once. Pulses matter more than constant exposure: in preconditioning studies, intermittent stimuli kept their protection, while daily nitroglycerin lost the endothelial preconditioning of a single exposure within a week.

Do not start with the gain knob

Nitrate donors, dietary nitrate, PDE5 inhibition, and pharmacologic eNOS phosphorylation are adjuncts. They do not replace coupled endothelial production or mitochondrial density. Nitrate-rich plants can feed the nitrate–nitrite–NO loop as an adjunct, not as a substitute for coupled eNOS. In someone whose flux is already high, a PDE5 inhibitor may shave a few millimeters of mercury; diminishing returns are the honest prediction. These are medicines and decisions for your own physician.

Cofactors, as information

The hypothesis lists targeted cofactors, PQQ, NR or NMN, CoQ10, and methylene blue in appropriate contexts, among the inputs that may support mitochondrial biogenesis, NAD+ pools, and redox balance. This is information, not a recommendation. Raising plasma CoQ10 or NAD without restoring fuel flexibility and flux is another check-engine-light reset. Meta-analyses of CoQ10 in hypertensive adults have reported average systolic reductions in the range of roughly 4–11 mmHg (with wide confidence intervals and heterogeneity); magnesium supplementation shows smaller average reductions (approximately 2–5 mmHg systolic in many analyses), larger in deficient or medicated individuals. Dietary nitrate (beetroot) produces acute and sometimes short-term reductions via the nitrate–nitrite–NO pathway. These effects are modest, context-dependent, and do not replace engine repair. Methylene blue carries an FDA boxed warning for serotonin syndrome with SSRIs, SNRIs, MAOIs and other serotonergic drugs, and it is avoided in G6PD deficiency and pregnancy; any use belongs with your own physician. Talk with your own physician before adding any supplement to blood-pressure treatment.

Things that push the wrong way

Some exposures push the same dashboard the wrong way. Chronic low-level COX inhibition with NSAIDs can worsen blood pressure, renal perfusion, and gut integrity. Thermal hormesis should not be stacked on depleted reserve, and uncontrolled hypertension is one of the named states where it can become plain stress. A GLP-1 agonist lowers systemic pressure, including nocturnal pressure, and can rewrite nocturnal perfusion faster than the matching apparatus can adapt. Talk with your own physician about any of these.

Conclusion

Primary hypertension, on this hypothesis, is not a disease of a number. It is the chronic chapter of a matching circuit. Nitric oxide is the gas with which the organism matches blood flow to mitochondrial demand, rations oxygen so the gradient reaches deep tissue, and keeps the conduit from becoming the disease. When the endothelium has ATP and redox headroom, eNOS stays coupled, shear stays laminar and pulsed, and the exercise rise in pressure is only the residue of delivery. When headroom erodes, the valve stays stiff, the wall remodels, the kidney resets, sympathetic and hormonal tone hold the set point, and the heart, the lungs, and the eye each pay a share of the bill.

The acute response, raising pressure to keep flow through underpowered tissue, belongs to the good side of the cascade. The standing high-pressure state does not. It is a scar: high resistance and a reset kidney, a delivery-system failure that then worsens the ratio of ATP output to demand. Pressure is the readout. Lowering it is often necessary and remains a physician's decision. It does not, by itself, recouple the synthase.

Prevention and treatment therefore begin with the conditions the engine evolved for: Fuel the nested symbionts can oxidize cleanly, Circadian timing that lets the endothelium and its mitochondria keep their daily rhythm, and Strength work that writes shear and mitochondrial volume so the acute loop can turn off. These interventions do not replace indicated pharmacologic therapy; they may address the upstream mismatch that makes those therapies necessary and reduce the probability that acute Crabtree-like compensations lock into Warburg architecture. As endothelial phenotyping and tissue-level measures of mitochondrial function mature, the hypothesis can be tested where it claims to be strongest, at the junction of delivery, consumption, and the simple toll-keeper on which the rest of biology still turns. If you live with high blood pressure, talk with your own physician about your own numbers and your own treatment.

This essay is a hypothesis, not medical advice. Individual evaluation by a qualified physician remains essential.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.

Related: Sage — Cardiology (Cardiopulmonary chapter) · Sage — Nitric Oxide · Sage — Cardiomyopathy and Heart Failure · Sage — Pulmonary · Sage — Calcium · Sage — Glaucoma · Sage — Warburg and Crabtree.

See the notice at the top of this page. Working hypothesis, not medical advice.